By ZUNAIDAH ZAINON
KUALA LUMPUR 13 Jan. - iNix Technologies Holdings Bhd. has submitted its application for registration with Malaysian National Pharmaceutical Regulatory Agency (NPRA) of Ministry of Health (MoH) in accordance with its earlier agreement to source vaccine for COVID-19 from China.
According to the statement, iNix said, the registration with NPRA is essential for the distribution of vaccine in Malaysia.
"As and when iNix has received the approval from MoH, the company would be able to import the vaccine and supply the same to MoH to conduct 3rd Phase Clinical Trial in which it would be fully sponsored by iNix as iNix’s CSR initiative.
"This first clinical trial in Malaysia is expected to involve approximately 3,000 volunteers," it said.
iNix, a wholly-owned subsidiary, INix Network Sdn. Bhd. are the supplier for COVID-19 vaccine from Sinovac Biotech Co Ltd, Cansino Biologics Inc and Sinopharm China National Biotech Group Co Ltd (CNBG)
Malaysia government has to ensure that only vaccines that meet the MoH's requirements will be registered and used in Malaysia.
This evaluation process is made by Product Evaluation Committee of NPRA and drugs control authority for approval before the COVID-19 vaccine can be used in Malaysia.
Yesterday, Prime Minister of Malaysia, Tan Sri Muhyiddin Yassin said, to achieve group immunity, as much as 60% to 70% or 20 to 23 million Malaysians need to be administered the COVID-19 vaccine.
For now, the government has already signed a preliminary agreement with Covax facilities, Pfizer and AstraZeneca for the procurement of the Covid-19 vaccines to secure the supply of vaccines for approximately 40% of the population.
The government is also in the final stage of negotiations with Sinovac, Cansino and Gamaleya to obtain a guaranteed vaccine supply for 80% of the total population of the country or 26.5 million. - DagangNews.com